M. Hassan

发表

Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients.

A. Lefvert, A. Osterborg, H. Mellstedt, 1994, Blood.

Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation

P. Ljungman, Moustapha Hassan, J. Aschan, 2006, Bone Marrow Transplantation.

Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI.

M. Remberger, O. Ringdén, G. Dahllöf, 2011, Oral diseases.

The role of busulfan in bone marrow transplantation

M. Hassan, 1999, Medical oncology.

The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity

P. Ljungman, O. Ringdén, A. Békássy, 2000, Bone Marrow Transplantation.

Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning

M. Remberger, O. Ringdén, B. Gustafsson, 2013, Pediatric transplantation.

The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo

M. Edgren, E. Hellström-Lindberg, Z. Hassan, 2002, Bone Marrow Transplantation.

The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro

E. Hellström-Lindberg, Z. Hassan, M. Hassan, 2001, Leukemia.

A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation

M. Remberger, O. Ringdén, Moustapha Hassan, 2008, Bone Marrow Transplantation.

Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen

O. Ringdén, A. Fasth, J. Abrahamsson, 2008, Bone Marrow Transplantation.

N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation

O. Ringdén, Z. Hassan, J. Aschan, 2003, Bone Marrow Transplantation.

Endometrial endothelial cells are derived from donor stem cells in a bone marrow transplant recipient.

J. Palmblad, M. Jansson, M. Mints, 2007, Human reproduction.

GVHD after chemotherapy conditioning in allogeneic transplanted mice

N. Aghdami, B. Rozell, Z. Hassan, 2008, Bone Marrow Transplantation.

Omega-3 from fish oil augments GVHD through the enhancement of chemotherapy conditioning regimen and selective FoxP3 depletion

M. Lindskog, Z. Hassan, M. Hassan, 2013, Bone Marrow Transplantation.

High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients

P. Ljungman, O. Ringdén, A. Békássy, 1997, Bone Marrow Transplantation.

The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model

M. Jansson, M. Mints, Z. Hassan, 2008, Bone Marrow Transplantation.

The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation

P. Ljungman, O. Ringdén, J. Aschan, 2003, Bone Marrow Transplantation.

Liposomal busulphan: bioavailability and effect on bone marrow in mice

Z. Hassan, M. Hassan, C. Nilsson, 1998, Bone Marrow Transplantation.

Pharmacokinetics of liposomal busulphan in man

P. Ljungman, O. Ringdén, J. Winiarski, 2001, Bone Marrow Transplantation.

Busulfan bioavailability.

Albert, Per, J. Starý, 1994, Blood.

A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m2 as a optimal total dose for conditioning

P. Ljungman, O. Ringdén, R. Seger, 2002, Bone Marrow Transplantation.

Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients

P. Ljungman, O. Ringdén, M. Sandström, 2001, Bone Marrow Transplantation.

A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation

C. Craddock, J. Goldman, J. Apperley, 2000, Leukemia.

Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2.

M. Wadhwa, C. Bird, R. Thorpe, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma.

A. Osterborg, J. Lundin, M. Hassan, 1999, European journal of haematology.

Bacterial lipopolysaccharide both renders resistant mice susceptible to mercury‐induced autoimmunity and exacerbates such autoimmunity in susceptible mice

J. Depierre, A. Zargari, M. Hassan, 2005, Clinical and experimental immunology.

Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation

M. Remberger, M. Uzunel, J. Mattsson, 2003, Bone Marrow Transplantation.

A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

M O Karlsson, M. Karlsson, P. Ljungman, 1999, British journal of clinical pharmacology.

Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome P450 genes by ciprofloxacin

L. Meurling, Moustapha Hassan, L. Griškevičius, 2003, Bone Marrow Transplantation.

Early-phase GVHD gene expression profile in target versus non-target tissues: kidney, a possible target?

A. Moshfegh, S. Al-Hashmi, Z. Hassan, 2013, Bone Marrow Transplantation.

Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants.

P. Ljungman, O. Ringdén, Moustapha Hassan, 1995, Bone marrow transplantation.

Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients

P. Ljungman, M. Hassan, G. Avetisyan, 2005, Bone Marrow Transplantation.

Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy.

P. Ljungman, O. Ringdén, J. Aschan, 2000, Therapeutic drug monitoring.

Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.

M. Basit, M. Maroules, F. Anwer, 2023, Leukemia research.